Taking people in FranceNo phase
Studies butyrophilin molecules in people with colon cancer
Measures butyrophilin molecules in colon cancer tumors to see if they predict disease course.
Key facts
- Who runs it
- Institut Paoli-Calmettes
- Where
- Marseille, FranceSee the site
- Trial code
- Registry title
- Butyrophilins Role in Colon Cancer
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 30 Jun 2020
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- analysis of BTN and BTNL status
- Record updated
- 1 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with colon cancer who are about to have surgery. It studies BTNL molecules as a possible marker of how aggressive the cancer is.
- Age
- Older than 18 years
- Sex
- All sexes can join.
- Disease stage
- Colon cancer without spread that can be removed by surgery right away, or colon cancer with liver spread found at diagnosis where colon and liver surgery are planned together.
- Earlier treatment
- Cannot have had treatment before surgery other than chemotherapy. Cannot have taken immune-suppressing drugs or long-course corticosteroids in the last 12 months.
Main reasons for not taking part
- Rectal cancer or colon cancer that has come back
- Colon cancer surgery needed as an emergency
- History of Crohn's disease or ulcerative colitis
- Pregnant or breastfeeding, or likely to be pregnant without effective contraception
- Unable to give consent or under legal protection measure
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patient is older than 18 years old,
- Signed participation consent,
- Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting
- Performance Status (PS) 0 or 1
- affiliated to the social security or beneficiary
Who cannot take part
- Patient who received neoadjuvant therapy other than chemotherapy
- Patient treated with immune-suppressors or long-course corticosteroids <12 months
- Rectal cancer, colon cancer recurrence
- Emergency of colon cancer Surgery
- History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis)
- Pregnant women or likely to be pregnant (without effective contraception) or breastfeeding,
- Person in urgent situation, person under legal protection measure, or unable to express his / her consent,
- Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons
Where in France
- Institut Paoli-CalmettesMarseille, FranceContact: Jihane PAKRADOUNI, PharmD, PhDTaking people
About the trial
What the trial wants to find out
quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer
The 2 groups in the trial
- non-metastatic colon cancerTreatment being tested
Treatment: analysis of BTN and BTNL status
- metastatic colon cancerTreatment being tested
Treatment: analysis of BTN and BTNL status
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Role of Butyrophilins in Colon Cancers Aggressiveness Evaluation
- Plain-language title
- Studies butyrophilin molecules in people with colon cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 October 2026